Skip to main content
Make a Gift

Stephan Moll, MD

Professor of Medicine

Dr. Moll is a clinician, clinical researcher, and educator, with a particular focus on thrombosis and anticoagulation. His research interests include clinical trials on venous thromboembolism and better use of anticoagulants, antiphospholipid antibody syndrome, and postthrombotic syndrome.

A major interest of Dr. Moll is the clinical-medical education of patients, health care professionals, the media, and the general public on venous thromboembolism and anticoagulation. He is a co-founder and the medical director of the UNC Blood Clot Information Program Clot Connect.

His clinical interest and expertise include unusual thromboses (e.g. cerebral and sinus vein thrombosis, retinal vessel thrombosis, splanchnic vein thrombosis, unexplained arterial thrombosis in the young), unusual thrombophilias (e.g. antiphospholipid antibodies; rare and compound thrombophilias), and unusual patient populations (e.g. high-level athletes).

Dr. Moll started the UNC “Athletes and Blood Clots Program” with the following aims: (1) to provide state-of-the-art comprehensive clinical care to high-level athletes, together with colleagues from UNC Sports Medicine, (2) to create and make available information/education for athletes and their families, physicians, trainers and coaches, the media and the general public; (3) to engage in and support clinical and basic research on high-level athletes.

Finally, Dr. Moll takes a special interest in supporting trainees in hematology and related fields in their career development involving the coagulation-hematologic topic.

References to most recent Clinical Research Activities include:

  1. Agnelli G et al for the Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29.
  2. Malpica Castillo LE, Palmer S, Zhu A, Deal AM, Chen SL, Moll S. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases. Am J Hematol. 2020 May;95(5):E117-E120. doi: 10.1002/ajh.25751. Epub 2020 Feb 17.
  3. Malpica-Castillo LE, Palmer S, Zhu A, Deal AM, Chen SL, Moll S. Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders. Am J Hematol. 2020 Mar;95(3):E72-E75.
  4. Mason SW, Barber A, Jones E, Chen SL, Moll S, Rohde K. Safety and efficacy of high-dose unfractionated heparin versus high-dose enoxaparin for venous thromboembolism prevention in morbidly obese hospitalized patients. Am J Med. 2019 Dec 17. pii: S0002-9343(19)31093-9. doi: 10.1016/j.amjmed.2019.12.003. [Epub ahead of print]
  5. Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, et al. Antiphospholipid Antibodies and Recurrent Thrombosis after a First Unprovoked Venous Thromboembolism. Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28.
  6. Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant therapy: an intermittent dosing strategy. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):412-417. doi: 10.1182/asheducation-2018.1.412.
  7. Lutsey PL, Horvath KJ, Fullam L, Moll S, Rooney MR, Cushman M, Zakai NA. Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients. Thromb Haemost. 2018 Mar;118(3):553-561. doi: 10.1055/s-0038-1625985. Epub 2018 Feb 15.